Date: Tuesday, May 18, 2021
Time: 9:00 am - 10:00 am USA Eastern Time (ET); 06:00 am - 07:00 am USA Pacific Time (PT)
Speakers: Barbara Nicke, Ph.D., Director of Therapeutic Compound Research, Nuvisan ICB GmbH, Germany; Dr. Paul Diehl, COO, Cellecta
This study will outline a target deconvolution strategy for novel potent small molecule inhibitors of YAP1/TAZ activity identified in a high-throughput screen of 3.8 million compounds. As a way to find the molecular target of the identified lead compound, pooled CRISPR/Cas9-KO screening targeting about 6000 human genes was conducted. PGGT1B, a subunit of the geranylgeranyltransferase I (GGTase I) complex, was validated as the direct target of the YAP1/TAZ pathway inhibitor.
In this presentation, you will learn about the:
A brief overview of Cellecta technologies and their application for drug target discovery and validation will follow the presentation.